Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)

Trial Profile

Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs Abicipar pegol (Primary) ; Ranibizumab
  • Indications Age-related macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 30 Jul 2014 Status changed from active, no longer recruiting to completed according to the ClinicalTrials.gov record.
    • 01 Jul 2014 Results published in the Molecular Partners AG Media Release.
    • 17 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top